Difference between revisions of "Alvocidib (Flavopiridol)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 14: | Line 14: | ||
*'''Code names:''' HMR 1275, L-868275 | *'''Code names:''' HMR 1275, L-868275 | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 22:15, 13 June 2018
Mechanism of action
From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO
Diseases for which it is used
History of changes in FDA indication
- 4/13/2007: Granted orphan status for treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.
- 4/23/2014: Granted orphan designation for the treatment of patients with acute myeloid leukemia (AML)
Also known as
- Code names: HMR 1275, L-868275